New 'Superopioid' Offers Pain Relief Without Opioid Side Effects

Promising study in Nature reveals a novel compound that activates the μ-opioid receptor without triggering addiction pathways.

Apr. 11, 2026 at 4:33pm

Got story updates? Submit your updates here. ›

An abstract, translucent X-ray image revealing the delicate, intricate structure of a human nerve cell, conveying the scientific complexity and potential breakthrough of the 'superopioid' discovery.A groundbreaking study explores a new 'superopioid' compound that could provide pain relief without the harmful side effects of traditional opioids.NYC Today

A new study published in Nature describes a promising 'superopioid' compound called DFNZ that provides effective pain relief in rodents without the typical opioid side effects like respiratory depression, tolerance, dependence, and addiction. The researchers found that DFNZ acts as a superagonist at the μ-opioid receptor but does not trigger the dopamine-driven reinforcement that leads to addiction, challenging the long-held assumption that strong μ-opioid activation inevitably causes these adverse effects.

Why it matters

The opioid crisis has devastated communities worldwide, making the development of safer pain medications a critical priority. This discovery suggests it may be possible to harness the pain-relieving properties of opioids without the risks of addiction and overdose, offering hope in the ongoing battle against the epidemic.

The details

The study, led by researchers at Gomez et al., used PET imaging and behavioral studies in rodents to extensively analyze the effects of DFNZ, a nitazene analog. They found that DFNZ provides effective analgesia for hours without triggering the respiratory depression, tolerance, and dependence typically associated with traditional opioids. Crucially, DFNZ did not induce the dopamine release and reinforcement that drives addiction, suggesting it may be possible to decouple the pain-relieving and addictive properties of opioids.

  • The study was published in the April 2026 issue of the journal Nature.

The players

Gomez et al.

The research team that conducted the study on the 'superopioid' compound DFNZ and its effects in rodent models.

DFNZ

A nitazene analog compound that acts as a superagonist at the μ-opioid receptor but does not trigger the dopamine-driven reinforcement that leads to addiction, according to the study.

Got photos? Submit your photos here. ›

What they’re saying

“This discovery may just be too good to be true. The study's findings are based on rodent models, and the compound is still very potent. It's crucial to approach this with caution and skepticism.”

— Dr. Singer, Pain management expert

“The DEA's decision not to schedule nitazenes as Schedule I drugs in 2019 allowed for research and the discovery of potentially beneficial compounds. This raises a broader question: what would have happened if the DEA had made nitazenes Schedule I drugs? The answer, as Dr. Singer points out, is that we might have missed out on this potential breakthrough.”

— Author

What’s next

Further research is needed to determine if the promising results in rodents can be replicated in human trials. Regulatory agencies will also need to carefully evaluate the safety and potential for abuse of DFNZ before it could be considered for clinical use.

The takeaway

This study offers a glimmer of hope in the ongoing battle against the opioid crisis, suggesting it may be possible to develop pain medications that provide relief without the risks of addiction and overdose. However, the findings are still preliminary, and significant additional research and regulatory scrutiny will be required before any new 'superopioid' could potentially reach the market.